Tafasitamab monotherapy

Author: gvqo

August undefined, 2024

WebApr 14, 2024 · Tafasitamab (12 mg/kg) was given for up to 12 cycles in combination with LEN (25 mg), then as monotherapy until disease progression (PD) or unacceptable toxicity. The primary endpoint was best objective response rate (ORR; complete response [CR] or partial response [PR], by independent radiology committee). WebAug 29, 2024 · On trial, patients received up to one year of both tafasitamab (12 mg/kg every 2 weeks) and lenalidomide (25 mg daily, 21/28 days) followed by tafasitamab monotherapy until progression. A total of 156 patients were screened, with 80 patients going on to receive both tafasitamab and lenalidomide.

Updated Data Confirm Long-Term Benefit With Tafasitamab

WebSep 18, 2024 · Tafasitamab as monotherapy displayed preliminary activity in 27 adults with relapsed or refractory CLL/SLL participating in a first-in-human, phase I, dose-escalation … WebJan 26, 2024 · Tafasitamab-cxix may be continued as monotherapy until patients experience disease progression or severe toxicity. Administration Premedicate at least 30 minutes prior to tafasitamab-cxix infusion with acetaminophen, histamine H 1 receptor antagonists, histamine H 2 receptor antagonists, and glucocorticoids. dennis bellamy death

A phase 3 study to evaluate the efficacy and safety of tafasitamab …

WebJun 15, 2024 · Responses with the combination of tafasitamab (MOR208) and lenalidomide (Revlimid) followed by tafasitamab monotherapy appear to be long-lasting with tolerable … WebMay 24, 2024 · Tafasitamab-cxix. Brand name: Monjuvi. Drug class: Antineoplastic Agents. Chemical name: Anti- (human CD19 antigen) (human-Mus musculus monoclonal … WebAug 3, 2024 · Tafasitamab monotherapy was associated with clinical activity in a subset of patients with R/R B-ALL, including short-lasting CR and MRD-negative CRi. Given its favorable tolerability profile, further … dennis benfield obituary

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with …

Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide …

WebAug 1, 2024 · The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and patients who are not eligible for autologous stem cell transplant. 1 WebJun 5, 2024 · Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. ffh one silent nightWebIt is interesting to note that patients with R/R DLBCL receiving lenalidomide monotherapy are being studied in an observational manner to serve as a comparator arm to those receiving tafasitamab, an antiCD19 anti-body NCT04150328). Of note, the data used in this analysis were censored in December 2024 and therefore preceded the US FDA approval ... dennis bergeron obituary

"WebApr 5, 2024 · Table 1 Tafasitamab monotherapy vs L-mind regimen in NHL. Full size table Selinexor is an inhibitor of exportin 1 (XPO1), the major nuclear export protein for a … " - Tafasitamab monotherapy

Tafasitamab monotherapy

AEs per patient-year during combination and monotherapy phases ...

WebTafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell … WebSep 7, 2024 · Tafasitamab dosing information. Usual Adult Dose for Lymphoma: 12 mg/kg IV (based on actual body weight; Administer in combination with lenalidomide 25 mg orally for a maximum of 12 cycles, then continue this drug as monotherapy until disease progression or unacceptable toxicity:

Did you know?

WebDec 12, 2024 · During a study, a small number of deadly side effects were reported. These included stroke, breathing problems, progressive multifocal leukoencephalopathy (PML; … WebDec 14, 2024 · In a phase 2 study, blinatumomab was used as second salvage in 41 patients with aggressive B cell lymphoma who failed platinum-based first salvage regimens, and got an ORR of 37% and CR rate of 22% after 12 weeks, indicating blinatumomab monotherapy to be an effective therapy that could bridge autologous stem cell transplantation (ASCT) in …

WebDuring the extended tafasitamab monotherapy phase, 21 (52.5%) patients had an interruption of tafasitamab treatment due to at least one TEAE, the most common … WebSep 7, 2024 · Tafasitamab dosing information. Usual Adult Dose for Lymphoma: 12 mg/kg IV (based on actual body weight; Administer in combination with lenalidomide 25 mg …

WebTafasitamab monotherapy has been shown to be effective in patients with R/R DLBCL, with a favorable safety profile 15; however, pregnant women were not included in this study and no safety data are currently available on single agent use of tafasitamab during pregnancy. Recommendation: LEN is contraindicated during pregnancy. No safety data are ... WebApr 4, 2024 · Toxicities that occurred during the first 12 cycles of combination therapy and toxicities with tafasitamab monotherapy in 37 patients, who either made it to a year or …

WebApr 4, 2024 · The trial is also evaluating pelabresib either as a monotherapy in patients who are resistant to, intolerant of, or ineligible for ruxolitinib and no longer on the drug (Arm 1) or as add-on therapy in combination with ruxolitinib in patients with a suboptimal response to ruxolitinib or myelofibrosis progression (Arm 2). ... Tafasitamab is a ...

WebJul 6, 2024 · AEs per patient-year during combination and monotherapy phases. 43 *n = 40 includes 30 patients who completed 12 cycles of tafasitamab plus lenalidomide and continued tafasitamab monotherapy and ... ff-hollersbachWebPatients received tafasitamab-cxix 12 mg/kg intravenously with lenalidomide (25 mg orally on days 1 to 21 of each 28-day cycle) for maximum of 12 cycles, followed by tafasitamab … ffhookWebNov 13, 2024 · Background: CD19 is broadly and homogeneously expressed across different B-cell malignancies and represents an attractive target antigen in patients with B-cell non … ffh one of these days lyricsWebIntroduction: Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell … dennis bergeron photographyWebMay 28, 2024 · These long-term data indicate the potential of tafasitamab + LEN followed by extended tafasitamab monotherapy in achieving prolonged remission and survival benefit in this patient population, especially at first relapse. Clinical trial information: NCT02399085. *No valid post-baseline response assessments. dennis benshoof obituaryWebJul 24, 2024 · Tafasitamab (MOR208) plus lenalidomide (Revlimid) followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival (OS) benefit in... dennis bergkamp scared of flyingWebIn Europe, Minjuvi® (tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). dennis berman family foundation